Want to see SE:SANION full AI Analyst Report?
SANION Stock Chart & Stats
kr21.10
-kr0.15(-2.06%)
At close: 4:00 PM EST
kr21.10
-kr0.15(-2.06%)
Day’s Range― - ―
52-Week Rangekr8.03 - kr28.30
Previous CloseN/A
Volume191.43K
Average Volume (3M)1.06M
Market Cap
kr1.75B
Enterprise Valuekr1.24B
Total Cash (Recent Filing)kr531.98M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)8.0
Beta0.02
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.59
Shares Outstanding138,030,140
10 Day Avg. Volume913,988
30 Day Avg. Volume1,064,614
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)4.30
Price to Sales (P/S)6.29
P/FCF Ratio13.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr11.00M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA zero-debt position materially improves financial flexibility and reduces funding risk for a small biotech. It lowers fixed obligations, supports sustained R&D spending and partnership negotiations, and increases resilience through clinical cycles over the next 2–6 months and beyond.
Strong Recent Cash GenerationPositive operating and free cash flow that meaningfully covers earnings indicates earnings quality and internal funding capacity. For a development-stage biotech, this supports ongoing trials and lowers near-term dilution risk, strengthening durability of operations.
Partnership-driven Development ModelA partnership-focused model spreads development risk and leverages external commercialization capabilities. Strategic collaborations can provide milestone and royalty streams, lower capital requirements, and improve long-term program viability across clinical stages.
Bears Say
Revenue VolatilityLarge swings in reported revenue reduce predictability of cash flows and complicate planning for R&D and commercialization. Reliance on lumpy milestone or partner payments can lead to uneven funding availability and higher execution risk over coming quarters.
Historical Financial InstabilityPrior periods of negative equity and heavy leverage demonstrate the firm's financial profile can shift quickly. While debt is currently nil, a return to unstable results could force dilutive financing or debt, raising structural funding risk for development programs.
Uneven Cash Flow GrowthRecent positive cash flow notwithstanding, negative free cash flow growth and past cash burn indicate cash generation may not be durable. This heightens the risk that future clinical or commercial timing could necessitate external funding or slow program advancement.
Saniona AB News
SANION FAQ
What was Saniona AB’s price range in the past 12 months?
Saniona AB lowest stock price was kr8.03 and its highest was kr28.30 in the past 12 months.
What is Saniona AB’s market cap?
Saniona AB’s market cap is kr1.75B.
When is Saniona AB’s upcoming earnings report date?
Saniona AB’s upcoming earnings report date is Aug 27, 2026 which is in 53 days.
How were Saniona AB’s earnings last quarter?
Saniona AB released its earnings results on May 26, 2026. The company reported -kr0.334 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.334.
Is Saniona AB overvalued?
According to Wall Street analysts Saniona AB’s price is currently Overvalued.
Does Saniona AB pay dividends?
Saniona AB does not currently pay dividends.
What is Saniona AB’s EPS estimate?
Saniona AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Saniona AB have?
Saniona AB has 138,030,140 shares outstanding.
What happened to Saniona AB’s price movement after its last earnings report?
Saniona AB reported an EPS of -kr0.334 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.884%.
Which hedge fund is a major shareholder of Saniona AB?
Currently, no hedge funds are holding shares in SE:SANION
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Saniona AB
Saniona AB (publ), founded in 2011 and based in Glostrup, Denmark, is a biopharmaceutical company focused on rare diseases. It specializes in discovering, developing, and commercializing treatments specifically targeting central nervous system disorders. The company's pipeline features Tesofensine, a monoamine reuptake inhibitor, and Tesomet, a fixed-dose combination of tesofensine and metoprolol, which has advanced through Phase 2 clinical trials for Prader-Willi Syndrome and hypothalamic obesity. Additionally, Saniona is progressing SAN711, currently in Phase 1 for rare neuropathic conditions, and SAN903, an early-stage candidate in preclinical development for rare inflammatory, fibrotic, and hematological ailments. Saniona also engages in various strategic collaborations, including research and partnership agreements with Boehringer Ingelheim International GmbH, a licensing deal with Productos Medix, S.A. de C.V., and both research services and collaboration agreements with Cephagenix ApS.
Technical Analysis
Oncopeptides AB
―
SynAct Pharma AB
―
Xbrane Biopharma AB
―
Xspray Pharma AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---